Impact of Angiotensin Receptor Blocker As Antihypertensive in Assessing Mortality in Patients of COVID-19: A Single Tertiary Care Center Study

Overview

Journal J Educ Health Promot

Specialty Medical Education

Date 2023 Apr 10

PMID 37034857

Authors

Sourya Acharya

Sunil Kumar

Ruchita Kabra

Mansi Patel

Neha Phate

Dhruv Talwar

Varun Daiya

Affiliations

Soon will be listed here.

Abstract

Background: The angiotensin-converting enzyme 2 (ACE2) receptor, a membrane receptor present in the respiratory system, the gastrointestinal tracts, the heart, and the kidney is the entry point for SARS-CoV-2 to enter human cells. Concerns were raised about the influence of using antihypertensive drugs like angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in individuals with COVID-19 due to its tight relationship with the ACE2 receptor. The aim of this study was to investigate the impact of being on an Angiotensin Receptor Blockers (ARB) on mortality in patients consecutively diagnosed with COVID-19.

Material And Methods: This is the retrospective observational study done in all patients consecutively diagnosed with COVID-19 from January 2021 to June 2021. All related patient information and clinical data was retrieved from the hospitals electronic medical record system.

Results: In this study, out of 500 patients, 51 died, having mean age of 66.92 ± 10.85 years. 144 (28.8%) patients were on angiotensin receptor blockers as antihypertensive treatment, 142 (28.4%) having other antihypertensive and 214 (42.8%) were not on any treatment. Out of 51 Death 7 (4.9) patients were on ARBs, 15 ± 10.6 were on other medication [OR 2.31 (0.94-6.22, = 0.077) univariable; OR 2.57 (1.00-7.23, = 0.058) multivariable] and 29 ± 13.6 had no treatment at all [OR 3.07 (1.38-7.80, = 0.010) univariable; OR 3.36 (1.41-9.08, = 0.010) multivariable].

Conclusion: Use of ARB medications for the hypertensive patients who acquire COVID-19 infection has shown protective effects of such medications on COVID-19 disease severity in the term of mortality and the mortality rate among hypertensive patients on COVID-19 with ARBs/ACE inhibitors showed significant differences as compared to other antihypertensives.

Citing Articles

Nonlinear Relationship Between Interleukin-6 and NT-proBNP at Admission in Hospitalized COVID-19 Patients.

Zhang M, Jiao Z Infect Drug Resist. 2023; 16:6259-6267.

PMID: 37753230 PMC: 10519174. DOI: 10.2147/IDR.S426470.

Factors Associated with Pneumonia in Patients Hospitalized with COVID-19 and the Role of Vaccination.

Zizza A, Sedile R, Bagordo F, Panico A, Guido M, Grassi T Vaccines (Basel). 2023; 11(8).

PMID: 37631910 PMC: 10458032. DOI: 10.3390/vaccines11081342.

References

Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D . Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020; 71(15):706-712. PMC: 7108195. DOI: 10.1093/cid/ciaa199. View

Zhou F, Liu Y, Xie J, Li H, Lei F, Yang H . Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality. Hypertension. 2020; 76(2):e15-e17. DOI: 10.1161/HYPERTENSIONAHA.120.15622. View

Lake M . What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020; 20(2):124-127. PMC: 7081812. DOI: 10.7861/clinmed.2019-coron. View

Flacco M, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A . Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020; 106(19):1519-1524. PMC: 7371482. DOI: 10.1136/heartjnl-2020-317336. View

Tetlow S, Segiet-Swiecicka A, OSullivan R, OHalloran S, Kalb K, Brathwaite-Shirley C . ACE inhibitors, angiotensin receptor blockers and endothelial injury in COVID-19. J Intern Med. 2020; 289(5):688-699. PMC: 7753609. DOI: 10.1111/joim.13202. View

Kumar S, Acharya S, Jain S, Shukla S, Talwar D, Shah D . Role of Zinc and Clinicopathological Factors for COVID-19-Associated Mucormycosis (CAM) in a Rural Hospital of Central India: A Case-Control Study. Cureus. 2022; 14(2):e22528. PMC: 8955911. DOI: 10.7759/cureus.22528. View

Wosten-van Asperen R, Lutter R, Specht P, Moll G, VAN Woensel J, van der Loos C . Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011; 225(4):618-27. DOI: 10.1002/path.2987. View

Sadeghipour P, Talasaz A, Rashidi F, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M . Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized.... JAMA. 2021; 325(16):1620-1630. PMC: 7974835. DOI: 10.1001/jama.2021.4152. View

Fang L, Karakiulakis G, Roth M . Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020; 8(4):e21. PMC: 7118626. DOI: 10.1016/S2213-2600(20)30116-8. View

10.

Talwar D, Kumar S, Acharya S, Raisinghani N, Madaan S, Hulkoti V . Interleukin 6 and Its Correlation with COVID-19 in Terms of Outcomes in an Intensive Care Unit of a Rural Hospital:A Cross-sectional Study. Indian J Crit Care Med. 2022; 26(1):39-42. PMC: 8783243. DOI: 10.5005/jp-journals-10071-24075. View

11.

Marashizadeh A, Sanati H, Sadeghipour P, Peighambari M, Moosavi J, Shafe O . Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial. Int Urol Nephrol. 2019; 51(10):1815-1822. DOI: 10.1007/s11255-019-02235-w. View

12.

Senkal N, Meral R, Medetalibeyoglu A, Konyaoglu H, Kose M, Tukek T . Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19. Anatol J Cardiol. 2020; 24(1):21-29. PMC: 7414823. DOI: 10.14744/AnatolJCardiol.2020.57431. View

13.

Braude P, Carter B, Short R, Vilches-Moraga A, Verduri A, Pearce L . The influence of ACE inhibitors and ARBs on hospital length of stay and survival in people with COVID-19. Int J Cardiol Heart Vasc. 2020; 31:100660. PMC: 7561344. DOI: 10.1016/j.ijcha.2020.100660. View

14.

Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B . Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005; 436(7047):112-6. PMC: 7094998. DOI: 10.1038/nature03712. View

15.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

16.

Jin Y, Cai L, Cheng Z, Cheng H, Deng T, Fan Y . A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020; 7(1):4. PMC: 7003341. DOI: 10.1186/s40779-020-0233-6. View

17.

Bean D, Kraljevic Z, Searle T, Bendayan R, Kevin O, Pickles A . Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail. 2020; 22(6):967-974. PMC: 7301045. DOI: 10.1002/ejhf.1924. View

18.

Ferrario C, Jessup J, Chappell M, Averill D, Brosnihan K, Tallant E . Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111(20):2605-10. DOI: 10.1161/CIRCULATIONAHA.104.510461. View